Zacks Research Predicts Reduced Earnings for AVANOS MEDICAL

Key Points

• AVANOS MEDICAL's Q4 2026 earnings per share estimates were lowered by Zacks Research from $0.38 to $0.37, with the current full-year earnings consensus at $1.32 per share.
• The stock was downgraded from a "strong-buy" to a "buy" rating by Wall Street Zen, while Zacks holds a "Hold" rating.
• Recent insider actions included Director Gary Blackford purchasing 40,000 shares for $439,600, indicating a significant increase in his position in the company.

AVANOS MEDICAL, INC. (NYSE:AVNS - Free Report) - Equities research analysts at Zacks Research reduced their Q4 2026 earnings per share (EPS) estimates for shares of AVANOS MEDICAL in a report issued on Tuesday, August 26th. Zacks Research analyst Team now anticipates that the company will earn $0.37 per share for the quarter, down from their previous forecast of $0.38. Zacks Research currently has a "Hold" rating on the stock. The consensus estimate for AVANOS MEDICAL's current full-year earnings is $1.32 per share.

Separately, Wall Street Zen downgraded AVANOS MEDICAL from a "strong-buy" rating to a "buy" rating in a research report on Saturday, August 9th. One investment analyst has rated the stock with a Hold rating, Based on data from MarketBeat.com, the stock has an average rating of "Hold".

AVANOS MEDICAL Trading Up 0.5%

AVANOS MEDICAL stock traded up $0.06 during trading hours on Friday, hitting $11.93. The stock had a trading volume of 647,282 shares, compared to its average volume of 820,234. The company has a quick ratio of 1.58, a current ratio of 2.64 and a debt-to-equity ratio of 0.12. The stock has a market cap of $553.74 million, a price-to-earnings ratio of -1.19 and a beta of 1.12. AVANOS MEDICAL has a one year low of $9.30 and a one year high of $25.36. The business's 50 day simple moving average is $11.62 and its 200-day simple moving average is $12.80.

AVANOS MEDICAL (NYSE:AVNS - Get Free Report) last posted its earnings results on Tuesday, August 5th. The company reported $0.17 EPS for the quarter, missing the consensus estimate of $0.18 by ($0.01). The firm had revenue of $175.00 million during the quarter, compared to the consensus estimate of $165.50 million. AVANOS MEDICAL had a negative net margin of 66.89% and a positive return on equity of 6.16%. During the same quarter in the prior year, the business posted $0.34 earnings per share. AVANOS MEDICAL has set its FY 2025 guidance at 0.750-0.950 EPS.

Insider Buying and Selling at AVANOS MEDICAL

In related news, Director Gary Blackford purchased 40,000 shares of the firm's stock in a transaction dated Wednesday, August 13th. The stock was bought at an average price of $10.99 per share, with a total value of $439,600.00. Following the completion of the purchase, the director owned 40,000 shares in the company, valued at approximately $439,600. This represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 2.64% of the company's stock.

Institutional Investors Weigh In On AVANOS MEDICAL

Several institutional investors and hedge funds have recently made changes to their positions in the stock. T. Rowe Price Investment Management Inc. increased its stake in shares of AVANOS MEDICAL by 24.8% in the first quarter. T. Rowe Price Investment Management Inc. now owns 3,757,576 shares of the company's stock valued at $53,847,000 after buying an additional 746,264 shares during the period. Armistice Capital LLC increased its stake in shares of AVANOS MEDICAL by 1.8% in the second quarter. Armistice Capital LLC now owns 2,036,000 shares of the company's stock valued at $24,921,000 after buying an additional 36,000 shares during the period. Brown Advisory Inc. increased its stake in shares of AVANOS MEDICAL by 1.4% in the first quarter. Brown Advisory Inc. now owns 1,931,163 shares of the company's stock valued at $27,674,000 after buying an additional 26,069 shares during the period. Tributary Capital Management LLC increased its stake in shares of AVANOS MEDICAL by 10.0% in the second quarter. Tributary Capital Management LLC now owns 810,720 shares of the company's stock valued at $9,923,000 after buying an additional 73,518 shares during the period. Finally, Qube Research & Technologies Ltd increased its stake in shares of AVANOS MEDICAL by 32.5% in the second quarter. Qube Research & Technologies Ltd now owns 625,409 shares of the company's stock valued at $7,655,000 after buying an additional 153,547 shares during the period. Institutional investors and hedge funds own 95.17% of the company's stock.

About AVANOS MEDICAL

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.